Astrazeneca (NYSE:AZN) Given “Sell” Rating at Deutsche Bank Aktiengesellschaft

Astrazeneca (NYSE:AZN)‘s stock had its “sell” rating reiterated by stock analysts at Deutsche Bank Aktiengesellschaft in a report issued on Thursday,MarketScreener reports.

AZN has been the subject of several other research reports. Wall Street Zen lowered Astrazeneca from a “buy” rating to a “hold” rating in a research note on Saturday, April 4th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Thursday. Barclays reaffirmed an “overweight” rating on shares of Astrazeneca in a research note on Tuesday, January 6th. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday. Finally, UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Astrazeneca presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.67.

Astrazeneca Price Performance

Shares of NYSE AZN traded down $1.58 during mid-day trading on Thursday, hitting $185.79. The company had a trading volume of 126,608 shares, compared to its average volume of 2,756,855. The stock has a market cap of $288.14 billion, a PE ratio of 31.35, a price-to-earnings-growth ratio of 1.40 and a beta of 0.35. Astrazeneca has a 1 year low of $132.32 and a 1 year high of $212.71. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.51 by $0.07. Astrazeneca had a return on equity of 31.01% and a net margin of 17.19%.The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.98 billion. Equities research analysts anticipate that Astrazeneca will post 10.26 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in AZN. Brighton Jones LLC grew its holdings in shares of Astrazeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after acquiring an additional 2,789 shares during the period. AQR Capital Management LLC grew its holdings in shares of Astrazeneca by 45.3% during the 1st quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after acquiring an additional 11,690 shares during the period. Amundi grew its holdings in shares of Astrazeneca by 54.4% during the 2nd quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after acquiring an additional 3,618 shares during the period. Jump Financial LLC grew its holdings in shares of Astrazeneca by 898.4% during the 2nd quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after acquiring an additional 30,125 shares during the period. Finally, Daiwa Securities Group Inc. grew its holdings in shares of Astrazeneca by 1.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock worth $3,259,000 after acquiring an additional 559 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Key Headlines Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: FDA panel backed AstraZeneca’s prostate cancer regimen, giving regulatory momentum to part of its oncology franchise — a near‑term positive for future approvals and revenues. Read More.
• Positive Sentiment: Strong Q1 results: AZN beat EPS and revenue expectations and reaffirmed 2026 guidance, supporting the company’s growth narrative driven by oncology and rare‑disease sales. Read More.
• Positive Sentiment: Citi raised its 2026 core EPS forecast and kept a Buy rating, highlighting attractive risk/reward ahead of multiple second‑half pipeline readouts. Analyst support can help underpin the stock. Read More.
• Positive Sentiment: DZ Bank upgraded AZN from Neutral to Buy, adding institutional endorsement to the bullish view after the earnings beat. Read More.
• Positive Sentiment: AstraZeneca exercised its option to license Pinetree’s EGFR degrader program (PTX‑299), triggering a $25M payment and expanding its targeted‑degrader pipeline — a financing and pipeline positive. Read More.
• Neutral Sentiment: Erste Group slightly trimmed its FY2026 EPS estimate for AZN (from $10.44 to $10.30), a modest forecast tweak that reflects caution but is close to consensus. Read More.
• Negative Sentiment: The key negative: an FDA Oncologic Drugs Advisory Committee voted 6–3 against recommending camizestrant for first‑line treatment in HR+ advanced breast cancer, citing trial‑design and benefit‑risk concerns — the vote has driven today’s share weakness and raises regulatory risk and potential delays for that indication. AstraZeneca says it will continue working with regulators. Read More.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.